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Background: Airborne transmitted pathogens, such as porcine reproductive and respiratory syndrome virus
(PRRSV), need to interact with host cells of the respiratory tract in order to be able to enter and disseminate in the
host organism. Pulmonary alveolar macrophages (PAM) and MA104 derived monkey kidney MARC-145 cells are
known to be permissive to PRRSV infection and replication and are the most studied cells in the literature. More
recently, new cell lines developed to study PRRSV have been genetically modified to make them permissive to the
virus. The SJPL cell line origin was initially reported to be epithelial cells of the respiratory tract of swine. Thus, the
goal of this study was to determine if SJPL cells could support PRRSV infection and replication in vitro.
Results: The SJPL cell growth was significantly slower than MARC-145 cell growth. The SJPL cells were found to
express the CD151 protein but not the CD163 and neither the sialoadhesin PRRSV receptors. During the course of
the present study, the SJPL cells have been reported to be of monkey origin. Nevertheless, SJPL cells were found to
be permissive to PRRSV infection and replication even if the development of the cytopathic effect was delayed
compared to PRRSV-infected MARC-145 cells. Following PRRSV replication, the amount of infectious viral particles
produced in SJPL and MARC-145 infected cells was similar. The SJPL cells allowed the replication of several PRRSV
North American strains and were almost efficient as MARC-145 cells for virus isolation. Interestingly, PRRSV is 8 to 16
times more sensitive to IFNα antiviral effect in SJPL cell in comparison to that in MARC-145 cells. PRRSV induced an
increase in IFNβ mRNA and no up regulation of IFNα mRNA in both infected cell types. In addition, PRRSV induced
an up regulation of IFNγ and TNF-α mRNAs only in infected MARC-145 cells.
Conclusions: In conclusion, the SJPL cells are permissive to PRRSV. In addition, they are phenotypically different
from MARC-145 cells and are an additional tool that could be used to study PRRSV pathogenesis mechanisms
in vitro.
Keywords: Porcine reproductive and respiratory syndrome virus, PRRSV, SJPL cells, Virus replication, Cell
permissivity, Type 1 IFN, IFNγ, TNF-α, Cytokines* Correspondence: carl.a.gagnon@umontreal.ca
1Groupe de recherche sur les maladies infectieuses du porc (GREMIP), Centre
de recherche en infectiologie porcine (CRIP), Faculté de médecine vétérinaire
Université de Montréal, 3200 rue Sicotte, Saint-Hyacinthe, J2S 7C6, Québec,
Canada
Full list of author information is available at the end of the article
© 2012 Provost et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited.
Provost et al. Virology Journal 2012, 9:267 Page 2 of 14
http://www.virologyj.com/content/9/1/267Background
Porcine reproductive and respiratory syndrome (PRRS)
is present worldwide and is economically speaking, one
of the most important infectious diseases in swine pro-
duction [1]. PRRS disease was first described in the Uni-
ted States in 1987 [2,3] and a few years later in the
Netherlands [4]. The disease has many clinical manifes-
tations but the two most prevalent are severe reproduct-
ive failure in sows and gilts (characterized by late-term
abortions, an increased number of stillborns, mummified
and weak-born pigs) [2,5] and respiratory problems in
pigs of all ages associated with a non-specific lympho-
mononuclear interstitial pneumonitis [2,5,6].
The etiological agent, porcine reproductive and re-
spiratory syndrome virus (PRRSV) was identified in
1991 by investigators in the Netherlands and shortly
after in the USA [4,7,8]. PRRSV is an enveloped, single-
stranded positive sense RNA virus, approximately 50–65
nm in diameter classified in the order Nidovirales, family
Arteriviridae, genus Arterivirus along with equine arter-
itis virus (EAV), lactate dehydrogenase-elevating virus of
mice (LDV), and simian hemorrhagic fever virus (SHFV)
[7,9]. PRRSV genome is approximately 15 kb in length.
The viral RNA genome is capped at the 5’ end and poly-
adenylated at the 3’ end and encodes at least ten open
reading frames (ORFs) [10-12], each of which is
expressed via the generation of a 3’-coterminal nested
set of subgenomic (sg) mRNAs [13]. The virus is genet-
ically, antigenically, and pathogenically heterogeneous
[14,15]. PRRSV isolates are currently divided into two
distinct genotypes, the European genotype (EU) or type
I represented by the Lelystad virus (LV) and the North
American genotype (NA) or type II represented by the
ATCC VR-2332 strain [16].
PRRSV is known to have a very restricted cell trop-
ism both in vivo and in vitro. In vivo, the virus infects
mainly well-differentiated cells of the monocyte-
macrophage lineage, in particular porcine alveolar
macrophages (PAMs), the primary target cells of virus
and interstitial macrophages in other tissues such as
heart, thymus, spleen and Peyer's patches, hepatic
sinusoids, renal medullary interstitium, and adrenal
gland [17-20]. In addition to macrophages, PRRSV
RNA and nucleocapsid protein (N) were found in tes-
ticular germ cells, endothelial cells in the heart, inter-
digitating cells in the thymus, dendritic cells in the
spleen and Peyer's patches [19,21]. In experimentally
infected gnotobiotic pigs, PRRSV antigens were found
in bronchiolar epithelial cells, arteriolar endothelial
cells, monocytes as well as interstitial, alveolar, and
intravascular macrophages using an immunogold-silver
immunohistochemical staining [22]. PRRSV RNAs and
antigens were also found in bronchiolar epithelial cells
[23], epithelium-like cells of alveolar ducts [24], andpneumocytes [23,25] in the naturally infected pigs whereas
they were not found in these types of cells in the experi-
mentally infected pigs [26]. Tissues such as lung, lymphoid
tissues, Peyer’s patches, and kidney were also the prefer-
able target organs of PRRSV infection [27,28].
In vitro, PRRSV was first isolated on primary cultures
of PAMs [4] and so far, these cells as well as freshly iso-
lated blood monocytes or monocytic derived dendritic
cells [29-31], remain the only non-genetically modified
porcine cells that can be used for viral propagation since
they can be infected by the virus and allow its replica-
tion. On the other hand, using primary cell lines present
some disadvantages as low number of cells harvested,
heterogeneity of the population, and more importantly
short lifespan of cells. Thus, using in vitro cell lines
present some benefits compared to primary cell lines.
There are two non-porcine permissive immortalized cell
lines that permit the complete replication cycle of
PRRSV, the MARC-145 and CL2621 cells (subclones of
MA104 monkey kidney cell line) [7,32,33] which are
routinely used for in vitro propagation of PRRSV and for
large scale production of PRRSV vaccine strains. More
recently, new cell lines have been genetically modified to
become permissive to PRRSV, as immortalized PAM
cells expressing the CD163 protein [34], immortalized
porcine monomyeloid cells expressing the human tel-
omerase reverse transcriptase [35], PK-15 cells expres-
sing the sialoadhesin protein [36], and porcine, feline
and baby hamster kidney cells expressing the CD163
protein [37]. Thus, all new reported cell lines have been
genetically modified to be permissive to PRRSV, leaving
room for the discovery of non-genetically modified
PRRSV permissive cell lines.
PRRSV can be airborne transmitted through long dis-
tance [38]. Airborne transmitted pathogens need to
interact with host cells of the respiratory tract such as
epithelial cells and alveolar macrophages in order to be
able to enter and disseminate in the host organism. If
PRRSV is airborne transmitted and PRRSV antigens and
viral RNA can be detected in epithelial cells of the re-
spiratory tract of infected pigs, then it can be speculated
that, in addition to the alveolar macrophages, epithelial
cells of respiratory tract could be permissive to PRRSV
replication in vitro. Nonetheless, no immortalized epi-
thelial cell of the respiratory tract of swine had been
reported so far to be permissive to PRRSV infection and
replication in vitro and attempts to find such cells have
previously failed [4,39,40].
Thus, St-Jude porcine lung cells (SJPL) cells, which
were at first reported to be an immortalized epithelial
cells line of the respiratory tract of swine and were pre-
viously described to be suitable for influenza virus repli-
cation [41], were tested for their PRRSV permissivity.
Noteworthy, during the course of this study, the SJPL
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karyotype and genetic analyses [42]. Nevertheless, the
results of the present study show that SJPL cells are: 1)
permissive to PRRSV replication and 2) phenotypically
different from MARC-145 cells.
Results
SJPL cells susceptibility to PRRSV
In order to evaluate the susceptibility of epithelial cells
of the respiratory tract of swine in regards to PRRSV,
two epithelial cell lines, the NPTr and SJPL cells, were
inoculated with PRRSV IAF-Klop strain at 1 multiplicity
of infection (MOI). As reported previously, the NPTr
cells were not permissive to PRRSV (data not shown)
[40]. However, the SJPL cells infected by PRRSV devel-
oped a very light cytopathic effect (CPE) at 72 hrs post-
infection (pi) compared to mock infected cells as
illustrated in Figure 1, which suggested the replication of
PRRSV. The amount of CPE observed in SJPL infected
cells increased over time but it has always been signifi-
cantly lower compared to PRRSV-infected MARC-145
cells (data not shown and Figure 1). The degree of CPE
at 120 hrs pi in PRRSV-infected SJPL cells was similar to
the amount of CPE observed at 72 hrs pi in PRRSV-
infected MARC-145 cells (data not shown). Interestingly,
the SJPL cells growth and cell dimension were higher
(doubling time: 32.57 ± 2.58 hrs, surface: 4684.41 ±
2188.94 μm2, respectively) compared to MARC-145 cells
(doubling time: 21.67 ± 3.30 hrs, surface: 3568.96 ±
1128.47 μm2, respectively) (Additional file 1: Figure S1).
To confirm the PRRSV proteins expression in SJPL
infected cells, an immunofluorescent assay (IFA) was
performed. The PRRSV N protein was detected in
PRRSV-infected SJPL cells (Figure 1) which indicates
that PRRSV was able to express at least the N viralFigure 1 Immunofluorescence detection of the N viral protein in PRR
the materials and methods section. Mock infected cells are illustrated as co
reference strain are illustrated in lower panels. Cells were visualized with vi
monolayer disruption induced by PRRSV infection.protein. Most of the IFA positive cells have positive sig-
nal localized in the cytoplasm (Figure 1) such as what
has been reported previously for PRRSV-infected
MARC-145 cells [43].
Identification of PRRSV receptors in SJPL cells
Three cellular molecules have been identified to play a
critical role in rendering non-permissive cells susceptible
to PRRSV infection: the CD163, CD151 and sialoadhesin
(Sn) [44-47]. Thus, the presence of these molecules in
SJPL cells was determined by an immunofluorescent
assay (Figure 2). As illustrated in Figure 2A, the SJPL
cells express the CD151 such as MARC-145 cells
(Figure 2I) and to a lower extent such as the PAM cells
(Figure 2E). The expression of CD163 and Sn proteins
was detected only in PAM cells (Figure 2F and 2G).
Infectious viral particles production in PRRSV-infected
SJPL cells
To establish if SJPL cells allow full PRRSV replication
cycle and infectious particles production after being in
contact with infectious virions, the amount of infectious
PRRSV particles produced by SJPL cells was evaluated
during five consecutive passages. As illustrated in
Figure 3, the amount of infectious virus yield from
the inoculum (103.3 TCID50/10
6 cells) compared to the
first passage in SJPL cells (106.6 TCID50/10
6 cells)
increased around 2000 times which indicates clearly that
SJPL permits the production of infectious viral particles.
The amount of virus yield was maintained during subse-
quent passages which further indicates that infectious
PRRSV particles are produced (Figure 3). However, the
overall production of infectious particles in SJPL cells
compared to MARC-145 cells does not seem to be sig-
nificantly different (P > 0.05).SV-infected SJPL cells. The IFA was done at 72 hrs pi as described in
ntrol in the upper panels. Cells infected at 1 MOI with PRRSV IAF-Klop
sible light (phase contrast) and UV (IFA). Arrows indicate the SJPL cell
Figure 2 Detection of PRRSV receptors in SJPL cell line by immunofluorescence. The IFA was done using specific antibodies directed
against CD151, CD163 and Sialoadhesin proteins in SJPL, PAM and MARC-145 cells. Negative control was obtained without primary antibody
exposition. As an example of results, the negative controls illustrated are the FITC conjugated anti-mouse. All cell nuclei were stained with DAPI.
Cells were visualized under UV exposition. Scale bar = 100 μm.
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tion in SJPL cells compared to MARC-145 cells, a
PRRSV replication kinetic experiment using type I and
type II PRRSV reference strains (LV and IAF-Klop, re-
spectively) has been conducted (Figure 4). Three signifi-
cant dual interactions of fixed-effect variables were
recorded: cell*matrix (P = 0.0224), cell*time (P =
0.0006), and matrix*time (P < 0.0001) (see methods sec-
tion for the definition). Thus, as expected, the increase
of the PRRSV titers over time was statistically significantFigure 3 Infectious viral particles production in PRRSV-infected
SJPL cells following five consecutive passages. PRRSV IAF-Klop
strain was passaged serially in MARC-145 and SJPL cells as described
in the materials and methods section. The amount of the infectious
viral particles recovered after each passage was determined in
MARC-145 cells. The virus titers were expressed as TCID50 per 10
6
cells. The initial viral inoculum (inocul) used to infect both cell lines
was 103.3 TCID50/10
6cells.for both cell types and both matrix (cell fractions and
supernatant fractions). The viral titers of the SJPL cell
fraction were 0.22 ± 0.08 TCID50 units (log10) lower
than the ones of MARC-145 cell fraction (P = 0.0806)
(Figure 4A), but those of the SJPL supernatants were
0.51 ± 0.08 TCID50 units (log10) lower than the ones of
MARC-145 supernatants (P < 0.01) (Figure 4B). In gen-
eral, around 10 times more infectious viruses have been
collected from the supernatant fraction compared to the
cell fraction (P ≤ 0.0002) (Figure 4A and 4C compared
to 4B and 4D, respectively). Moreover, the areas under
the time-TCID50 curves (AUC) results indicated that the
overall estimation of PRRSV infectious virions produc-
tion of the SJPL cells averaged 98% of those of MARC-
145 cells for cell fractions (Figure 4A) and 90% for
supernatant fractions (Figure 4B).
Virus isolation efficiency
Overall, 22 cases were tested. Three were PRRSV real-
time PCR negative and used as controls. From the 19
PRRSV real-time PCR positive cases, 11 PRRSV isolates
were obtained using MARC-145 cells compared to 8
with SJPL cells (Table 1). Consequently, the virus isola-
tion efficiency with MARC-145 and SJPL cells were 58%
and 42%, respectively, suggesting that MARC-145 could
be slightly more suitable for PRRSV virus isolation from
clinical samples. In addition, all virus isolation positive
cases with SJPL cells were also virus isolation positive
with MARC-145 cells. Interestingly, when the amount of
PRRSV was higher than 500 TCID50 of PRRSV/gram of
tissue, the virus isolation efficiency was also very high
for both cell lines. More precisely, the virus isolation
Figure 4 PRRSV replication kinetics in SJPL cells. MARC-145 and SJPL cells were infected at 1 MOI with PRRSV IAF-Klop (A, B) and LV (C, D)
strains. At different time pi, the infectious viruses recovered from the cell culture medium (B, D: supernatant fraction) and the cells (A, C: cell
fraction) were titered in MARC-145 cells. Experiment was done in triplicate.
Provost et al. Virology Journal 2012, 9:267 Page 5 of 14
http://www.virologyj.com/content/9/1/267efficiency for tissues that have > 500 TCID50 of PRRSV/
gram was 100% and 88% for MARC-145 and SJPL cells,
respectively (Table 1). To further characterize the
PRRSV strains that were isolated, the ORF5 gene of five
cases that were both virus isolation positive with
MARC-145 and SJPL cells were sequenced. Sequence
analyses revealed that all PRRSV strains are type II iso-
lates (data not shown). The nucleotide (nt) identities
between the tissues and the fourth cell passage in both
cell lines of each cases were 100% identical indicating
that the same PRRSV strains, that were identified ini-
tially in the tissues, were isolated. Moreover, at the
fourth cell passage, the ORF5 sequences of virusesTable 1 PRRS virus isolation efficiency from swine









0-100c 0 / 7 0 / 7
101-500 2 / 6 0 / 6
501-2500 7 / 7 6 / 7
2501-40000 2 / 2 2 / 2
Total: 11 / 22 8 / 22
aThe PRRSV was quantified as previously described using a real-time PCR
assay [67].
bThe virus isolation were attempted with both cell lines using the same swine
tissue homogenates.
cThree cases out of 7 were real-time PCR negative for the presence of PRRSV.isolated from each porcine tissue homogenate in SJPL
and MARC-145 cells were 100% identical which sug-
gests that SJPL cells allow the isolation of the same
strains as those isolated with MARC-145 cells. Se-
quence analyses also revealed genetic variability be-
tween strains that were isolated from each porcine
tissue homogenate with SJPL cells (86.4% to 93.2% nt
identities) and compared to the PRRSV reference strain
IAF-Klop (88.3% to 91.0% nt identities).
PRRSV-induced apoptosis in SJPL cells
As illustrated in Figure 5, the procaspases 3/7 activation
by the IAF-Klop PRRSV reference strain and several
apoptotic inducers was more pronounced in SJPL cells
compared to MARC-145 cells (2.7 to 4.4 times higher).
In addition, activation of procaspases 3/7 in PRRSV-
infected MARC-145 and SJPL cells was 3.5 to 6.2 times
higher (P < 0.05), respectively, compared to noninfected
cells (Figure 5). Even if procaspases 3/7 activation was
higher in SJPL cells, at the time the cells were disrupted
(24 hrs and 72 hrs pi), the CPE was very mild in SJPL
cells compared to MARC-145 cells (Figure 1). At least
60% of the MARC-145 infected cells showed CPE com-
pared to SJPL cells which showed mild if no CPE.
Inhibition of PRRSV replication
To evaluate the impact of IFNα in regards to PRRSV
replication, different amounts of IFNα were added in the
cell culture media of both cell lines. Interestingly, the
minimal concentration of IFNα needed to have an
Figure 5 Procaspases 3/7 activation in SJPL cells infected by
PRRSV. MARC-145 and SJPL cells were infected at 0.5 MOI with
PRRSV IAF-Klop strain or incubated with a combination of four
apoptotic inducers (actinomycin D, vinblastine sulfate, cycloheximide
and puromycin) as a positive control. At 24 hrs post-incubation with
the apoptotic inducers, MARC-145 cells have developed high CPE
level compared to SJPL cells which showed low to mild CPE. At 72
hrs, PRRSV infected cells were disrupted for the detection of caspase
3 using a specific fluorogenic substrate. The results were expressed
as relative fluorescence released (relative fluorescence units or RFU)
per second per μg of cell lysates. Values are presented as ± standard
deviation (SD). When 2 sets of data within a cell type are labeled
with superscripts of different letters or when only one set is labeled
with a superscript, it indicates that these 2 sets of data are
statistically different (P < 0.05). When 2 sets of data from different
cell types are labeled with asterisk, it indicates that these 2 sets of
data are statistically different (*** P < 0.001).
Table 2 Minimal concentration of IFNα for the inhibition






MARC-145 > 6.25, < 12.5a > 50, < 78.13
SJPL > 0.78, < 1.56 > 3.13, < 6.25
aExpress in U/μL.
Note: the experiment was done in duplicate.
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times lower in SJPL cells (between 0.78 to 3.13 U/μL)
compared to MARC-145 cells (between 6.25 to 50 U/
μL) (Table 2), showing that SJPL cells are more sensitive
to IFNα than MARC-145 cells.
Effect of PRRSV on cytokine mRNAs expression
Since the sensibility to IFNα PRRSV inhibition was dif-
ferent between SJPL and MARC-145 cells, the level of
mRNA expression of different cytokines known to be
regulated following different viral infections, such as
IFNα, IFNβ, IFNγ, and TNF-α, [48], was evaluated. As
previously described, PRRSV infection in MARC-145 or
in PAM cells induced an increase of IFNβ, IFNγ and
TNF-α, but not of IFNα mRNAs expression [49-53]
(Figure 6). On the other hand, PRRSV infection only
induced an increase expression of IFNβ, and not of the
other tested cytokines mRNA in infected SJPL cells
compared to MARC-145 cells, where PRRSV inducedIFNβ, IFNγ, and TNF-α mRNAs. Transfecting SJPL and
MARC-145 cells with Poly (I:C) as a positive control
induced an increase of IFNβ, IFNγ and TNF-α mRNAs
in both cell types but no increase of IFNα mRNA was
observed. However, SJPL cells were found to have a
basal level of expression of IFNα mRNA similar to
MARC-145 cells (data not shown) suggesting their abil-
ity to produce the protein. Furthermore, Poly (I:C)
increased the relative expression of IFNβ, IFNγ and
TNF-α mRNAs in a similar way in both MARC-145 and
SJPL cells, suggesting that both cell types can produce
the tested mRNA cytokines. Interestingly, LPS was not
able to induce IFNγ mRNA expression in both cell lines.
Statistical analyses indicated that the relative expression
of IFNβ, IFNγ and TNF-α mRNAs are significantly dif-
ferent between PRRSV-infected MARC-145 and SJPL
cells, adding another evidence that the two cell lines are
responding differently following PRRSV infection.
Discussion
Previous attempts to find porcine immortalized cell
lines, not genetically modified, into which PRRSV infec-
tious particles could bind, enter and complete a full virus
replication cycle including infectious virions production,
such as epithelial cell line of the respiratory tract, have
failed [4,39,40]. In the present study, a new immortalized
cell line, the SJPL cells [41], was found to be permissive
to PRRSV infection and replication (Figures 1, 3 and 4).
At the beginning of this project, the SJPL cells were
reported to be epithelial cells of the respiratory tract of
swine [41,54]. During the course of this study however,
these cells were found to be of monkey origin [42], sug-
gesting that they could be phenotypically similar to
MARC-145 cells, another monkey cell line. In addition,
the SJPL cells have been known to be permissive to a
variety of sub-types of influenza virus from human,
swine, avian and horse origins [41]. From now on,
PRRSV can be added to the list of viruses that can repli-
cate in SJPL cells.
Although, the SJPL cells were found to be phenotypic-
ally distinguishable from the MARC-145 cells based on
cell growth curve (Additional file 1: Figure S1), cell di-
mension (Figure 1), and CPE development following
PRRSV infection (Figure 1), the amount of infectious
Figure 6 Relative expression of IFNα (A), IFNβ (B), IFNγ (C) and TNF-α (D) mRNA of SJPL and MARC-145 cells induced by PRRSV.
MARC-145 and SJPL cells were infected at 0.5 MOI with PRRSV IAF-Klop strain or transfected with poly (I:C) as a positive control or treated with
LPS as an IFNγ inducer. mRNA relative expression of IFNα (A), IFNβ (B), IFNγ (C) and TNF-α (D) was measure at 72 hrs by qRT-PCR in PRRSV
infected or poly (I:C) treated cells. Values are presented as ± standard deviation (SD). When 2 sets of data within a cell type are labeled with
superscripts of different letters or when only one set is labeled with a superscript, it indicates that these 2 sets of data are statistically different
(P < 0.05). When 2 sets of data from different cell types are labeled with asterisk, it indicates that these 2 sets of data are statistically different
(* P < 0.05, ** P < 0.01, *** P < 0.001).
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was similar to PRRSV-infected MARC-145 indicating
that those differences do not seem to affect the virus
production. In addition, it is suggesting that SJPL could
replace the MARC-145 cells (and related cells that deriv-
ate from MA104 cells) in a large scale PRRSV live or
killed vaccine production. Interestingly, even if SJPL cells
seem to be slightly less sensitive for PRRSV isolation
compared to MARC-145 cells (Table 1), the SJPL cells
were able to allow the replication of several PRRSV
type II ORF5 genomic variants and the type I refe-
rence strain LV (Figure 4 and Table 1) indicating that
at least these cells are permissive to a wide spectrum
of PRRSV isolates.
The IFNα antiviral effect against PRRSV-infected
MARC-145 cells has been previously reported [55]. Con-
sequently, different amount of IFNα were added in the
cell culture media to evaluate its antiviral effect in
regards to both PRRSV-infected cell lines. It was found
that SJPL cells are more responsive to the IFNα antiviral
effect than MARC-145 cells (Table 2). The level of cyto-
kine mRNA expressions measured by qRT-PCR was dif-
ferent between SJPL and MARC-145 cells. As previously
demonstrated in other studies, PRRSV infection in
MARC-145 or PAM cells induced an increase in IFNβ,IFNγ and TNF-α mRNA expressions [49-53] and similar
results were obtained in this study. On the other hand,
in SJPL cells, PRRSV infection only induced IFNβ
mRNA expression at much lower amount compared to
MARC-145 infected cells, indicating that PRRSV might
escape IFN type I and other cytokines responses
[31,56,57]. Several published reports showed that PRRSV
contained an ability to suppress the IFNβ activity at the
transcription level [49,58,59]. All those studies looked ei-
ther at the promoter induction (Luciferase assay) or at
the mRNA level by qRT-PCR at 0 hr until 48 hrs post-
infection (pi). In the present study, IFNβ mRNA was
quantified at a different time pi compared to previous
studies, i.e. at 72 hrs pi, which could explain the differ-
ence that has been observed. In Genini and collaborators
(2008), a strong induction of IFNβ mRNA was observed
in PRRSV-infected PAM cells with a variation in time pi,
i.e.:, no induction at 0 hr, induction at 3 hrs pi, no induc-
tion at 6 hrs pi and very strong induction at 9 and
12 hrs pi, illustrating that there is a variation in time of
IFNβ mRNA level that does not seem to be constant
and proportional [53]. Furthermore, Lee and collabora-
tors (2004), have reported that different strains of
PRRSV are able to induce distinctive interferon pheno-
types in vitro indicating that the induction of cytokines
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[60]. In the present study, a different PRRSV strain (IAF-
Klop) was used compared to previous reports which
might explain the differences in cytokine mRNA pheno-
type that was observed. Thus, those results demonstrate
the importance of using more than one in vitro model to
study PRRSV replication cycle and pathogenesis.
Many studies have demonstrated that PRRSV induces
apoptosis both in vitro and in vivo [21,61-64] and several
techniques have been used to demonstrate that
phenomenon, such as procaspase 3 activation in PRRSV
IAF-Klop infected MARC-145 cells [65]. The CPE visua-
lized by light microscopy in PRRSV-infected SJPL cells
was very mild and was delayed over time compared to
PRRSV-infected MARC-145 cells (Figure 1, data not
shown, respectively). The increase in TNF-α mRNA
obtained with qRT-PCR in infected MARC-145 cells and
the absence of its up regulation in infected SJPL cells
(Figure 6) could support the difference observed in CPE.
Consequently, amount of caspase 3 in MARC-145 cells
infected by PRRSV is expected to be higher compared to
SJPL cells infected by PRRSV. Surprisingly, the opposite
situation was observed indicating that SJPL cells are
more suited for procaspases 3/7 activation than MARC-
145 cells (Figure 5). This latest result demonstrates
clearly that SJPL cells are phenotypically completely dif-
ferent from MARC-145 cells and that the level of pro-
caspases 3/7 activation and TNF-α mRNA expression
induced by PRRSV may not be related to the level of
CPE that could be observed by light microscopy. In fact,
other cell death mechanisms have been reported to
occur in cells infected by PRRSV such as necrosis which
could explain this difference observed between the cell
lines [30,66].
Conclusions
In conclusion, SJPL cells are phenotypically different from
MARC-145 cells and they respond differently to PRRSV
infection (Figures 1, 5, and 6, Tables 2, Additional file 1:
Figure S1). SJPL cells have also been shown to represent a
convenient in vitro model for the study of porcine bacterial
pathogens [54]. Thus, studying the PRRSV-SJPL interac-
tions should give us new insight in regards to the viral
pathogenesis of PRRSV. In addition, SJPL cells could serve




MARC-145 cells, which are a subclone of the African
green monkey kidney MA104 cells that is highly per-
missive to PRRSV [33], were maintained as described
previously [59]. The St. Jude porcine lung (SJPL) epithe-
lial cell line was provided kindly by Dr R.G. Webster(St. Jude Children's Hospital, Memphis, TN, USA) [41].
During this study, karyotyping and genome sequence
analyses of the SJPL cells revealed that their species ori-
gin was not porcine but was rather monkey [42]. The
newborn pig trachea epithelial cell line (NPTr) was pro-
vided kindly by Dr. M. Ferrari (Instituto Zooprofilattico
Sperimental, Brescia, Italy) [40]. The SJPL and NPTr cell
lines were cultured in Dulbecco’s modified Eagle’s
medium (DMEM) (Invitrogen Corporation, GibcoBRL,
Burlington, ON, Canada) supplemented with 10% fetal
bovine serum (FBS) (Wisent Inc, St-Bruno, QC,
Canada), 1 mM sodium pyruvate, 2 mM L-glutamine,
1 μM MEM nonessential amino acids, 10 U/mL of
penicillin, 10 μg/mL of streptomycin and 250 g/L
antibiotic-antimycotic solution (Invitrogen Corporation,
GibcoBRL) as described previously [40,41]. Pulmonary
alveolar macrophages (PAMs) were used as a positive
controls for the detection of PRRSV receptors. PAMs
were harvested from lungs of 2 to 14 weeks old pigs.
Pigs were sacrificed following ethic protocol 12-Rech-
1640 approved by the Institutional ethic committee
following the guidelines of the Canadian Council on
Animal Care (CCAC). Briefly, an instillation of the lungs
with PBS containing 10 units/mL penicillin, 10 μg/mL
streptomycin and 100 mg/L gentamicin (Invitrogen Cor-
poration, GibcoBRL) was realized. Then, PBS was col-
lected and PAMs removed following low speed
centrifugation. Cells were washed with medium DMEM
complemented with 2 mM L-glutamine, 0,1 mM HEPES,
1 μM Non-essential amino acids (Invitrogen Corpor-
ation, GibcoBRL), 250 g/L Amphotericin B (Wisent Inc),
10 units/mL penicillin, 10 μg/mL streptomycin and
100 mg/L gentamicin. Cells were then collected follow-
ing low speed centrifugation and were resuspended in
freezing medium (same as wash medium plus 20% fetal
bovine serum (Wisent Inc.) and 10% DMSO (Sigma,
St-Louis, MO, USA)) and slowly frozen, than stored in
liquid nitrogen until further utilization. PAMs were cul-
tured for 24 hours in complete DMEM prior the im-
munofluorescence assay. All cell lines were cultured at
37°C in 5% CO2 atmosphere.
The PRRSV strain used to establish the permissivity of
the SJPL cells was the MARC-145 cells adapted IAF-
Klop North American reference strain [65] and the
Lelystad (LV) European reference strain [23]. The
PRRSV virus stocks were obtained following three cycles
of freeze-thaw of PRRSV MARC-145 infected cells.
Afterward, the virus was purified following a 3.5 hrs
period of ultracentrifugation on a 30% sucrose cushion
(in a TBS solution: 50mM tris pH7.5, 150mM NaCl)
using the SW28 Beckman Coulter rotor at 83,000 rela-
tive centrifugal force (rcf ). The virus pellets were resus-
pended in 0.5 mL of PBS and aliquots of the virus stocks
were then conserved at –70°C for future use. The
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96-well microplate of MARC-145 infected cells by the
Kärber method as described previously [67]. Virus titers
were expressed in tissue culture infectious dose 50% per
mL (TCID50/mL).
Immunofluorescence assay (IFA) for the detection of
PRRSV antigen
The presence of PRRSV antigens in infected cells was
determined by an immunofluorescence assay (IFA).
Briefly, cells infected by PRRSV strains were fixed at dif-
ferent times post-infection (pi) with a 4% paraformalde-
hyde (PFA) solution prepared as described previously
[68]. Mock-infected cells were included as negative con-
trols. After an incubation period of 30 minutes at room
temperature, the PFA solution was removed and cells
were washed three times with a phosphate buffer saline
solution (PBS). Then, cells were incubated during
10 minutes at room temperature with a PBS solution
containing 1% Triton X-100. After removing the Triton
X-100 solution, the cells were washed three times with a
PBS-Tween 20 solution (PBS containing 0.02% Tween
20). After the permeabilization procedure, cells were incu-
bated 30 minutes with PBS containing 0.2% Tween 20
and 1% Fetal Bovine Serum Albumin. Then, the α7 rabbit
monospecific antisera (a specific anti-N PRRSV protein
antibody) [65] was diluted 1/200 in the washing buffer
and added to the cells and incubated at room temperature
for a 30 minutes period. Cells were then washed and incu-
bated for 30 minutes with the washing buffer containing a
1/160 dilution of anti-rabbit specific antisera FITC conju-
gated (Sigma-Aldrich Inc., St-Louis, USA). Finally, cells
were visualized using a DMI 4000B reverse fluorescence
microscope, image of the cells were taking with a DFC
490 digital camera and the image were analyzed using the
Leica Application Suite Software, version 2.4.0 (Leica
Microsystems Inc., Richmond Hill, Canada).
Immunofluorescence assay for PRRSV receptors CD151,
CD163, and Sialoadhesin detection
The presence of CD151, CD163 and Sialoadhesine (Sn)
proteins in MARC-145, SJPL and PAM cells was deter-
mined by an IFA. Briefly, cells were fixed with a 4% PFA
solution as described previously [68]. After an incuba-
tion period of 30 minutes at room temperature, the PFA
solution was removed and cells were washed three
times with PBS. Then, cells were incubated with a
permeabilization and blocking solution, PBS solution
containing 0.1% Triton X-100, 7% normal sheep serum
(NSS) and 5% non fat dry milk (NFDM), during 30 min-
utes at room temperature. After removing the
permeabilization/blocking solution, the cells were
washed three times with a PBS. Then, cells were incu-
bated overnight with primary antibodies. All thoseantibodies were diluted 1/100 in antibody solution con-
taining PBS, 0.1% Triton X-100, 1.4% NSS, and 1%
NFDM. The antibodies used were: rabbit polyclonal
anti-human CD151 (Santa Cruz Biotechnology, CA,
USA); mouse monoclonal anti-pig CD163 (AbD Serotec,
Oxford, United Kingdom) for PAMs cells or goat poly-
clonal anti-human CD163 (Santa Cruz Biotechnology,
CA, USA) for MARC-145 and SJPL cells; mouse mono-
clonal anti-pig CD169 (synonym: Sialoadhesin, Siglec-1)
(AbD Serotec, Oxford, United Kingdom) for PAMs cells
or goat polyclonal anti-human Siglec-1 (Santa Cruz Bio-
technology, CA, USA) for MARC-145 and SJPL cells.
The anti-CD163 and anti-CD169 polyclonal antibodies
are known to react against several animal species. Their
reactivity was confirmed against the PAMs control posi-
tive cells (data not shown). Thereafter, cells were washed
three times and incubated for 60 minutes with the anti-
body buffer containing a 1/160 dilution of anti-rabbit
specific antisera FITC conjugated (Sigma-Aldrich Inc.,
St-Louis, USA) or 1/200 dilution of anti-mouse specific
antisera FITC conjugated (ICN Immuno Biological, CA,
USA). Nuclei were stained with 4',6-diamidino-2-pheny-
lindole DAPI (Sigma-Aldrich Inc., St-Louis, USA) as
recommended by the manufacturer. Negative controls
were obtained from cells where only the primary anti-
body was omitted. Cells were visualized the same way as
described above.
Virus production during multiple cell passages
An amount of 106 MARC-145 or SJPL cells were
infected with 0.005 MOI of IAF-Klop strain. Then, cells
with their supernatants were subjected to three cycles of
freeze-thaw at -70°C and the virus stock solutions were
kept at -70°C for future use. Four subsequent viral pas-
sages in MARC-145 and SJPL cells were done as
described above except that a dilution of 1/20 of the pre-
vious viral stock solutions was used for cell infection.
Mock-infected cells were included as controls in each
passage. The amount of virus production at each passage
was calculated from a 96-well microplate of MARC-145
infected cells by the Kärber method and the results were
expressed in tissue culture infectious dose 50% per 106
infected cells (TCID50/10
6 cells).
Virus replication kinetics assay
105 MARC-145 and SJPL cells were infected with IAF-
Klop and LV strains using an MOI of 1. At different
times pi (0, 4, 9, 12, 18, 24, 48, 72, 96 and 120 hrs),
whole cell cultures were collected and were processed
by low speed centrifugation to separate the cell pellet
(cell fraction) from the culture medium (supernatant
fraction). Both fractions were stored at -70°C until used.
Afterwards, virus titration was performed in MARC-145
cells as described above. Mock-infected cells were
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were repeated two times in triplicate.
Virus isolation
Virus isolation was attempted from 22 swine samples
(lung and lymph nodes tissues) submitted from October
2007 to September 2008 to the Veterinary virology diag-
nostic laboratory of the Veterinary College of the Uni-
versité de Montréal. Those samples originated from 3
to 10 weeks old animals housed in different Canadian
farms and they were submitted for different reasons
such as PRRSV outbreaks, porcine circovirus associated
disease outbreaks, or others health problems. Three of
the submitted samples were PRRSV negative by a real-
time PCR diagnostic assay (Tetracore Inc., Rockville,
MD, USA) and the amount of infectious PRRSV con-
tained in the 19 real-time PCR positives cases was
determined using the same assay as described previ-
ously [67]. For virus isolation, about 1-2 cm3 of pool of
tissue samples were homogenized and resuspended in
9 mL of culture medium without FBS. Then, three cycles
of freeze-thaw at -70°C were performed and tissues
homogenates were centrifuged and the supernatants
were filtered (with a filter size of 0.2 micron). Following
the sample treatment, 1 mL of filtered sample was used
to inoculate cells and cells were incubated for 5 days.
Then, three cycles of freeze-thaw were performed at
-70°C and cell lysates were centrifuged at 4000 rpm for
10 min. Supernatants of cell lysates were collected and
used for a subsequent cell infection cycle. One mL of the
cell lysate supernatants was inoculated to freshly pre-
pared cell cultures and cells were incubated for 5 days.
This new infection step was done for three consecutive
times. At the fourth passage, the virus isolation status
was confirmed by the presence of CPE and a positive IFA
result. To further characterize the PRRSV strains that
were isolated from both cell lines, PCR products encom-
passing the ORF5 gene were obtained from tissues and
fourth virus isolation cell passages, and sequenced subse-
quently. Sequences were analyzed using the CLUSTAL
W alignment method of the BioEdit sequence alignment
editor version 7.0.9 software (Ibis Therapeutics, Carlsbad,
CA, USA).
Apoptosis
MARC-145 and SJPL cells were infected with PRRSV
IAF-Klop strain at 0.5 MOI or were incubated with a
mix of apoptotic inducers (500 μg/mL actinomycin D,
60 nM vinblastine sulfate, 100 μg/mL cycloheximide and
40 μg/mL puromycin 2HCl; Biomol Research Laborator-
ies Inc., Plymouth meeting, PA, USA) as positive con-
trols. Cellular changes associated with the infection or
the inducers were visualized respectively at 72 hrs pi and
24 hrs post-incubation, respectively, under a lightmicroscope (Leica Microsystems Inc.). At this time, cells
were disrupted in a lysis buffer (50 mM HEPES, pH 7.4,
100 mM NaCl, 0.1% CHAPS, 1 mM DTT and 100 μM
EDTA) for 5 minutes followed by sonication (Sonifier
S-450A, Branson, Danbury, CT, USA). Then, protein
concentrations were measured by a Bradford assay fol-
lowing the manufacturer’s instructions (Bio-Rad Labora-
tories Ltd, Mississauga, ON, Canada). Subsequently,
apoptosis was assessed by detecting the activation of pro-
caspases 3/7 as described by Gagnon et al. (2003), with
minor modifications [65]. Briefly, a volume of cell lysate
corresponding to 50 μg of total cell protein was added to
the assay buffer (50 mM HEPES, pH 7.4, 100 mM NaCl,
0.1% CHAPS, 1 mM DTT, 100 μM EDTA and 10%
glycerol). Then, specific substrate for caspases 3/7, the
Ac-DEVD-AFC fluorogenic substrate (Biomol Research
Laboratories Inc.), was added at a final concentration of
200 μM and the rate of fluorescence released was moni-
tored with a 96-well plate fluorometer (Synergy HT,
Biotek, Winooski, VT, USA). The results were expressed
as relative fluorescence released (relative fluorescence
units or RFU) per second per μg of cell lysates.
Inhibition of PRRSV replication
To determine the amount of porcine IFNα that is able to
inhibit the replication of PRRSV in permissive cell lines,
104 MARC-145 and SJPL cells were incubated overnight.
The cells were then infected with the PRRSV IAF-Klop
strain at an infectious dose of 0.5 MOI in a culture
medium without FBS and incubated during 4 hrs. The
culture medium was then removed and replaced by a
complete medium (i.e. with 10% FBS) with different seri-
ally diluted concentrations of porcine IFNα (PBL, New
Jersey, USA) and incubated during 5 days. Then, the de-
velopment of CPE was monitored and an IFA was per-
formed. All the experiments were done in duplicate.
Analysis of cytokine mRNAs expression by real time
reverse transcriptase-quantitative PCR
SJPL and MARC-145 cells were infected as described
above or transfected with Polyinosinic–polycytidylic acid
potassium salt (Poly (I:C) [50 μg/mL] (Sigma-Aldrich
Inc., St-Louis, USA) as a positive control for innate im-
munity induction, using polyethylenimine (PEI) [1 μg/
μL] (Sigma-Aldrich Inc., St-Louis, USA), for 72 hours or
treated with 1μg/ml of lipopolysaccharide (LPS) (Sigma-
Aldrich Inc., St-Louis, USA) for 20 hours, as an IFNγ in-
ducer. Total cellular RNA was extracted from cells using
Trizol reagent (Invitrogen, Burlington, ON, Canada)
according to the manufacturer’s protocol. Quantification
of RNA was performed with a Nanodrop (NanoDrop
Technologies, Inc., Wilmington, Delaware, USA). 1 μg of
total RNA was reverse-transcribed using the QuantiTect
reverse transcription kit (Qiagen, Mississauga, ON,
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EvaGreenW Supermix kit (Bio-rad, Hercules, CA, USA).
The PCR amplification program for all cDNA consisted
of an enzyme activation step of 3 min at 98°C, followed
by 40 cycles of a denaturing step for 2 sec at 98°C
and an annealing/extension step for 5 sec at 58°C. The
primers used for amplification of the different target






CTACAACATGGGC. All primers were tested to achieve
amplification efficiency between 90% and 110%. The pri-
mer sequences were all designed from the NCBI Gen-
Bank mRNA sequences using web-based software
primerquest from Integrated DNA technologies [69]. The
Bio-Rad CFX-96 sequence detector apparatus was used
for the cDNA amplification. The quantification of differ-
ences between the different groups was calculated using
the 2-ΔΔCt method. Beta-2 microglobulin (B2M) was used
as the normalizing gene to compensate for potential dif-
ferences in cDNA amounts. The B2M primers from mon-
key origin used are F-GTGCTATCTCCACGTTTGAG
and R-GCTTCGAGTGCAAGAGATTG. The non-
infected MARC-145 and SJPL cells were used as the cali-
brator reference in the analysis.
Statistical analyses
A two-way ANOVA model, followed by Bonferroni post-
hoc tests (Graphpad PRISM Version 5.0 software) were
used to determine if a statistically significant difference
exists between MARC-145 and SJPL cell lines in regards
to the amount of PRRSV produced after multiple cell
passages, procaspases 3/7 activation and cytokines
mRNA up regulation in PRRSV infected cells and in
Poly (I:C) transfected cells. One-way ANOVA model,
followed by Tukey's Multiple Comparison Test (Graph-
pad PRISM) were used to determine if a statistically sig-
nificant difference exists between treatments within
MARC-145 or SJPL cells in procaspases 3/7 activation
and their mRNA relative expression of IFNα, IFNβ,
IFNγ, and TNF-α. Differences were considered statisti-
cally significant with a p<0.05. For the viral replication
kinetic experiment, the time-course of TCID50 measured
from the cell pellets and supernatants was analyzed with
SAS Version 9.1 software. The following linear mixed-
effect model for repeated measurements was solved
using restricted maximum-likelihood estimation [70]:
Yijkl = μ + αi + βj + τk + (α·β)ij + (α·τ)ik + (β·τ)jk + (α·β·τ)
ijk + R·(α·β)ijl + eijkl. Where Yijkl is the measured TCID50;
μ is the grand mean; cell line (αi), type of analytical
matrix (βj), and sampling time (τk) are fixed factors; theexperiment replicate (Rl) is a random effect; and eijkl is
the random error term. As indicated in the equation
above, this statistical model included all dual and triple
interactions between the fixed-effect factors, and the
random-effect factor Rl was nested within cell and ana-
lytical matrix. The strategy for covariance structure
modeling proposed by Littell et al (2000) was used [71].
Briefly, the model was estimated first with a free covari-
ance structure. After inspecting the estimated covariance
matrix, the model was estimated anew with more parsi-
monious covariance models (e.g., compound symmetry,
first-order autoregressive), which structure resembled
that of the unstructured covariance matrix. The hetero-
geneous first-order autoregressive covariance model was
selected because it was the best fit to the empirical co-
variance matrix, as determined with the Akaike informa-
tion criterion [71]. Least-square means were used to
assess differences between the two cell lines at each time
and for each type of analytical matrix (i.e., cell or super-
natant fractions), using Bonferroni-adjusted significance
thresholds. The areas under the time-TCID50 curves
(AUC) were calculated for each cell*matrix*replicate in
order to obtain estimates of total viral production for each
cell line following the 120 hrs duration of the experiment.Additional file
Additional file 1: Figure S1. SJPL and MARC-145 cells growth curves.
Amount of cells (log2) was calculated with a hemacytometer at seeding
time (0 hr), and at 24, 48, and 72 hrs post-incubation. Doubling time was
calculated with data obtained at 24 and 48 hrs post-incubation with the
formula: Doubling time (hrs) = 0.3 X incubation time (hrs) / (log cell time
b- log cell time a), where incubation time is 24 hrs, cell time a is the
amount of cells at 24 hrs and cell time b is the amount of cells at 48 hrs.
Interestingly, the MARC-145 cells grow faster than the SJPL cells. During
this experiment, cells surface areas were calculated with ImageJ v.1.6.0
from three different pictures of each cell type at 24 hrs post-incubation.
SJPL and MARC-145 cells have a surface area of 4684.41 ± 2188.94 μm2
(n = 29) and 3568.96 ± 1128.47 μm2 (n = 38), respectively. Statistical
analyses using t test showed that SJPL cells have a statistically wider
surface than MARC-145 cells (P < 0.01) (data not shown).Abbreviations
AUC: Areas under the time-TCID50 curves; B2M: Beta-2 microglobulin;
CPE: Cytopathic effect; EAV: Equine arteritis virus; EU: European genotype;
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elevating virus; LPS: Lipopolysaccharide; LV: Lelystad virus; N: Nucleocapsid
protein; NA: North American genotype; NPTr: Newborn trachea epithelial cell
line; ORF: Open reading frame; PAM: Porcine alveolar macrophages;
PBS: Phosphate buffer saline solution; PCV: Porcine circovirus; PCV2: Porcine
circovirus type 2; PEI: Polyethylenimine; PFA: Paraformaldehyde; Pi: Post-
infection; Poly (I:C): Polyinosinic–polycytidylic acid potassium salt;
PRRS: Porcine reproductive and respiratory syndrome; PRRSV: Porcine
reproductive and respiratory syndrome virus; Rcf: Relative centrifugal force;
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